Adial Pharmaceuticals Inc (ADIL)
US Market

Adial Pharmaceuticals (ADIL) Income Statement


Adial Pharmaceuticals Income Statement

Last quarter (Q4 2023), Adial Pharmaceuticals's total revenue was $450.00K, an increase of 233.41% from the same quarter last year. In Q4, Adial Pharmaceuticals's net income was $-1.92M. See Adial Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 450.00K$ 450.00K$ 134.97K-$ 0.00$ 0.00
Cost of Revenue
$ -10.00K-$ 550.00K$ -40.00K--
Gross Profit
$ 460.00K$ 450.00K$ -415.03K$ 40.00K--
Operating Expense
$ 1.05M$ 6.89M$ 13.32M$ -19.29M$ 10.93M$ 8.24M
Operating Income
$ -1.05M$ -6.89M$ -13.32M$ -17.74M$ -10.93M$ -8.24M
Net Non Operating Interest Income Expense
$ 69.78K$ 69.78K$ 63.21K$ 6.54K$ 32.49K$ 95.23K
Other Income Expense
$ 183.72K$ 183.72K$ -522.00K$ 235.22K$ 2.50K$ -441.76K
Pretax Income
$ -7.00M$ -7.00M$ -12.73M$ -19.52M$ -10.89M$ -8.59M
Tax Provision
$ 690.03K$ 690.03K$ -502.00$ -94.08K$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ 718.12K$ -5.12M$ -12.73M$ -19.42M$ -10.89M$ -8.59M
Basic EPS
$ -4.55$ -7.19$ -0.51$ -1.04$ -0.87$ -0.87
Diluted EPS
$ -0.95$ -3.59$ -0.51$ -1.05$ -0.87$ -0.87
Basic Average Shares
$ 31.10M$ 1.42M$ 25.04M$ 18.59M$ 12.46M$ 9.85M
Diluted Average Shares
$ 31.10M$ 1.42M$ 25.04M$ 18.59M$ 12.46M$ 9.85M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 1.04M$ 6.89M$ -13.87M$ -19.33M$ 10.93M$ 8.24M
Net Income From Continuing And Discontinued Operation
$ -5.12M$ -5.12M$ -12.73M$ -19.42M$ -10.89M$ -8.59M
Normalized Income
$ -3.24M$ -5.53M--$ -10.89M$ -8.15M
Interest Expense
-----$ 0.00
$ -7.00M$ -7.00M$ -12.73M$ -19.52M$ -10.93M$ -8.24M
$ -7.00M$ -7.00M$ -12.67M$ -19.46M$ -10.93M$ -8.24M
Currency in USD

Adial Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis